LawPlayer
My bookmarksSign up freeSign up free
Source

Commission Implementing Decision (EU) 2020/414 of 19 March 2020 amending Implementing Decision (EU) 2019/570 as regards medical stockpiling rescEU capacities (notified under document C(2020) 1827) (Text with EEA relevance)

Commission Implementing Decision (EU) 2020/414 of 19 March 2020 amending Implementing Decision (EU) 2019/570 as regards medical stockpiling rescEU capacities (notified under document C(2020) 1827) (Text with EEA relevance)

Implementing Decision (EU) 2020/414 · Decision · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Total estimated costs of medical stockpiling rescEU capacities

Article 1

Open ↗

Implementing Decision (EU) 2019/570 is amended as follows: (1) Article 1 is amended as follows: — point (d) is replaced by the following: ‘(d) total estimated costs of emergency medical team type 3 rescEU capacities;’; — the following point (e) is added: ‘(e) total estimated costs of medical stockpiling rescEU capacities.’; (2) Article 2 is amended as follows: (a) in paragraph 1, the third indent is replaced by the following: ‘— emergency medical team capacities,’; (b) in paragraph 1, the following fourth indent is added: ‘— medical stockpiling capacities.’; (c) in paragraph 2, the point (e) is amended as follows: ‘(e) emergency medical team type 3 capacities: Inpatient Referral Care;’ (d) paragraph 2, following point (f) is added: ‘(f) stockpiling of medical countermeasures or personal protective equipment aimed at combatting serious cross-border threats to health, as referred to in Decision No 1082/2013/EU of the European Parliament and of the Council  ( *1 ) . ( *1 )   Decision No 1082/2013/EU of the European Parliament and of the Council of 22 October 2013 on serious cross-border threats to health and repealing Decision No 2119/98/EC ( OJ L 293, 5.11.2013, p. 1 )’;" (3) the following Article 3c is inserted: ‘Article 3c Total estimated costs of medical stockpiling rescEU capacities 1.   All cost categories referred to in Annex IA to Decision No 1313/2013/EU shall be taken into account when calculating the total estimated cost of medical stockpiling rescEU capacities. 2.   The equipment costs of the total estimated costs of medical stockpiling rescEU capacities shall be calculated on the basis of market prices at the time when the capacities are acquired, rented or leased in accordance with Article 12(3) of Decision No 1313/2013/EU. Where Member States acquire, rent or lease rescEU capacities, they shall provide the Commission with documentary evidence of the actual market prices or, where there are no market prices for certain components of those capacities, with equivalent evidence. 3.   The categories of the total estimated costs of medical stockpiling rescEU capacities referred to in points 2 to 8 of Annex IA to Decision No 1313/2013/EU shall be calculated at least once during the period of each multiannual financial framework, taking into account information available to the Commission, including inflation. That calculation of the total estimated costs shall be used by the Commission for the purpose of providing annual financial assistance. 4.   The total estimated cost referred to in paragraphs 2 and 3 shall be calculated where at least one Member State expresses interest in acquiring, renting or leasing a medical stockpiling rescEU capacity.’; (4) the Annex is amended as set out in the Annex to this Decision.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX In the Annex, the following Section 6 is added: ‘6. Stockpiling of medical countermeasures and/or personal protective equipment aimed at combatting serious cross-border threats to health Tasks — Stockpiling of medical countermeasures, comprising of vaccines or therapeutics, intensive care medical equipment, personal protective equipment, or laboratory supplies, for the purpose of preparedness and response to a serious cross-border threat to health  ( 1 ) . Capacities — Adequate number of doses of vaccines necessary for individuals considered to be at risk  ( 2 ) linked to one or more cases of serious cross-border threats to health. — Adequate number of doses of therapeutics necessary to treat one or more cases of serious cross-border threats to health. — Vaccines and therapeutics shall fulfil one of the following requirements: — Marketing authorisation from EMA; — A positive recommendation for compassionate or emergency use from EMA or a national regulatory agency of a Member State; — A positive recommendation for expanded or emergency use from WHO and acceptance by at least one National Regulatory Agency of a Member State. — Adequate intensive care medical equipment  ( 3 ) , to provide supportive care to one or more cases of serious cross-border threats to health, in accordance with WHO standards. — Adequate number of sets of personal protective equipment  ( 4 ) for individuals considered to be at risk  ( 5 ) linked to one or more cases of serious cross-border threats to health, in accordance with the standards of the ECDC and the WHO. — Adequate number of laboratory supplies, including sampling material, laboratory reagents, equipment and consumables  ( 6 ) , to ensure laboratory diagnosis capacity for one or more cases of serious cross-border threats to health. Main components — Appropriate storage facilities in the Union  ( 7 ) and adequate stockpiling monitoring system. — Appropriate procedures ensuring the adequate packaging, transport and delivery of the products referred to under capacities, where needed. — Appropriately trained personnel to handle, and administer the products referred to under capacities. Deployment — Availability for departure maximum 12 hours after the acceptance of the offer. ( 1 )   As defined in Decision No 1082/2013/EU. ( 2 )   Individuals considered at risk may comprise: high risk potential contacts, first responders, laboratory workers, health care workers, family members and other defined vulnerable groups. ( 3 )   This may comprise, but is not limited to, intensive care ventilators. ( 4 )   Covering the following categories: (i) eye protection; (ii) hand protection; (iii) respiratory protection; (iv) body protection; and (v) foot protection. ( 5 )   See footnote 2. ( 6 )   This may include, but is not limited to, RT-PCR reagents, such as enzymes, RNA extraction reagents, RNA extraction machine time, PCR machine time, primer and probe reagents, positive control reagents, PCR laboratory consumables (e.g. tubes, plates) and disinfectants. ( 7 )   For the purposes of the logistics of storage facilities, “in the Union” encompasses the territories of Member States and Participating States of the Union Civil Protection Mechanism.’

Other acts of the same type
Council Decision (EU) 2021/651 of 19 April 2021 on the signing, on behalf of the Union, of the Agreement in the form of an Exchange of Letters between the European Union and the Argentine Republic pursuant to Article XXVIII of the General Agreement on Tariffs and Trade (GATT) 1994 relating to the modification of concessions on all the tariff-rate quotas included in the EU Schedule CLXXV as a consequence of the United Kingdom’s withdrawal from the European UnionCommission Decision (EU) 2021/660 of 19 April 2021 amending Decision (EU) 2020/491 on relief from import duties and VAT exemption on importation granted for goods needed to combat the effects of the COVID-19 outbreak during 2020 (notified under document C(2021) 2693)Council Implementing Decision (CFSP) 2021/636 of 16 April 2021 implementing Decision 2013/798/CFSP concerning restrictive measures against the Central African RepublicCouncil Decision (CFSP) 2021/613 of 15 April 2021 amending Decision (CFSP) 2016/1693 concerning restrictive measures against ISIL (Da’esh) and Al-Qaeda and persons, groups, undertakings and entities associated with themCommission Implementing Decision (EU) 2021/627 of 15 April 2021 laying down rules on keeping and accessing of the logs in the European Travel Information and Authorisation System (ETIAS) pursuant to Regulation (EU) 2018/1240 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2021/659 of 15 April 2021 concerning exemptions from the extended anti-dumping duty on certain bicycle parts originating in the People’s Republic of China pursuant to Regulation (EC) No 88/97 (notified under document C(2021) 2416)Commission Implementing Decision (EU) 2021/609 of 14 April 2021 amending Implementing Decision (EU) 2020/439 as regards harmonised standards on packaging for terminally sterilised medical devices and sterilisation of health care productsCommission Implementing Decision (EU) 2021/610 of 14 April 2021 amending Implementing Decision (EU) 2020/437 as regards harmonised standards on medical vehicles and their equipment, anaesthetic and respiratory equipment, biological evaluation of medical devices, packaging for terminally sterilised medical devices, sterilisation of health care products, clinical investigation of medical devices for human subjects, non-active surgical implants, medical devices utilising animal tissues and their derivatives, electroacoustics and medical electrical equipmentCommission Implementing Decision (EU) 2021/611 of 14 April 2021 amending Implementing Decision (EU) 2020/438 as regards harmonised standards on biological evaluation of medical devices, packaging for terminally sterilised medical devices, sterilisation of health care products and clinical investigation of medical devices for human subjectsCommission Decision (EU, Euratom) 2021/625 of 14 April 2021 on the establishment of the primary dealer network and the definition of eligibility criteria for lead and co-lead mandates for syndicated transactions for the purposes of the borrowing activities by the Commission on behalf of the Union and of the European Atomic Energy CommunityCommission Implementing Decision (EU) 2021/626 of 14 April 2021 establishing the InvestEU Portal and setting out its technical specificationsCouncil Implementing Decision (CFSP) 2021/585 of 12 April 2021 implementing Decision 2011/235/CFSP concerning restrictive measures directed against certain persons and entities in view of the situation in Iran

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next